Literature DB >> 2736678

Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug.

F Zunino1, G Pratesi, A Micheloni, E Cavalletti, F Sala, O Tofanetti.   

Abstract

Reduced glutathione has been shown to be an effective protector against cisplatin-induced nephrotoxicity of potential clinical value, since it does not reduce antitumor activity of the cytotoxic drug. This paper extends previous observations on the protective potential of reduced glutathione against cisplatin-induced nephrotoxicity, in different rodent models. Following i.v. administration, glutathione protection against cisplatin-induced nephrotoxicity was found to be critically dependent on timing of thiol administration. Whereas the sulfhydryl compound provided almost complete protection in CD rats, the protective effect against toxic renal damage was only partial in mice of different strains. In spite of the modest protection against kidney toxicity, glutathione reduced lethal toxicity in the mouse. Under the same experimental conditions at protective dose levels, the tripeptide thiol did not interfere with the antitumor effectiveness of cisplatin, in any of the tumor models examined. The kidney content of non-protein sulfhydryls of CD rats produced by the effective dose of glutathione was markedly higher than that found in the mouse treated with the same dose. This finding is consistent with a differential protection provided by glutathione against cisplatin-induced renal toxicity in these species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736678     DOI: 10.1016/0009-2797(89)90065-3

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  23 in total

1.  Pluchea lanceolata protects against Benzo(a) pyrene induced renal toxicity and loss of DNA integrity.

Authors:  Tamanna Jahangir; Mohammed M Safhi; Sarwat Sultana; Sayeed Ahmad
Journal:  Interdiscip Toxicol       Date:  2013-03

2.  Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine.

Authors:  Takeji Saitoh; Hiroshi Satoh; Mamoru Nobuhara; Masashi Machii; Takamitsu Tanaka; Hayato Ohtani; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

Review 3.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.

Authors:  M Links; C Lewis
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

5.  The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin.

Authors:  Roohangiz Safaei; Preston L Adams; Mohammad H Maktabi; Ryan A Mathews; Stephen B Howell
Journal:  J Inorg Biochem       Date:  2012-03-03       Impact factor: 4.155

Review 6.  Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Authors:  Akiko Nakayama; Karen P Alladin; Obianuju Igbokwe; Jeffrey D White
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

7.  Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system.

Authors:  K Husain; C Morris; C Whitworth; G L Trammell; L P Rybak; S M Somani
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

8.  Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs.

Authors:  P Perego; A Boiardi; N Carenini; M De Cesare; E Dolfini; I Magnani; S Martignone; A Silvani; C Soranzo
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine.

Authors:  L Hogarth; M English; L Price; R Wyllie; A D Pearson; A G Hall
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Authors:  D M Vail; A A Elfarra; A J Cooley; D L Panciera; E G MacEwen; S A Soergel
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.